Accolade To Present at Upcoming Investor Conferences
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the...
Year: 2024
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s diseaseBETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) --...
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
BioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical studySAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE)...
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Alimera Sciences Names Elliot Maltz as Chief Financial Officer Elliot Maltz, CFO of Alimera Sciences ATLANTA, Jan. 02, 2024 (GLOBE...
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
VANCOUVER, British Columbia, Jan. 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Court Finds Corcept Therapeutics’ Patents Not Infringed
MENLO PARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
Anavex Life Sciences Provides an Update on Rett Syndrome Program
Anavex Announces Topline Results from Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome Validation from Real World Evidence (RWE)...
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and...
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company...
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
SHANGHAI, China, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company...
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract...
XOMA Announces Stock Repurchase Program of up to $50 Million
Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that...
Streamline Health® Expands Agreement With Existing eValuator™ Client to Add RevID™
6 facility New York health system becomes first client leveraging both eValuator and RevID to improve revenue integrity pre-bill Atlanta,...
Branded Legacy, Inc. ($BLEG) Retires Additional 442 Million Common Shares, Surpassing Initial Commitment
MELBOURNE, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- via IBN — Branded Legacy (OTC: BLEG) is further highlighting its commitment...
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
Trogarzo® IM maintenance dosing aims to further enhance the convenience of non-oral therapy for heavily treatment-experienced adults with HIV Submission...
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing...